News
News Center
2021-04-14
Moving forward, we hope to leverage the "first-mover advantage" and pioneering policies of the Lecity Pilot Zone, along with its initiatives in real-world data research, to fast-track the approval and launch of Jiuzhitang's innovative products in China. By doing so, we aim to deliver valuable health solutions and services to people worldwide, solidifying our position as the public’s top-choice health partner and ultimately contributing even greater value to global human health!
+
2021-04-09
As regenerative medicine continues to advance and refine, stem cell therapy has already brought hope to countless patients suffering from previously intractable diseases. Looking ahead, stem cells are poised to make even greater strides in treating a wider range of illnesses, offering renewed optimism to more patients in the years to come.
+
2021-04-02
On April 1, 2021, JD Health officially established a strategic partnership with the time-honored brand Jiuzhitang. The two companies will collaborate across multiple areas, including retail of pharmaceuticals and greater health products, academic marketing, the "Yaojingcai" supply chain, and internet-based healthcare resources.
+
2021-04-01
Attention, working professionals: Lack of sleep can seriously shorten your lifespan.
People often feel both curiosity and fear toward new developments. Bone marrow mesenchymal stem cells have gone from being questioned in the past to gradually gaining acceptance—and now, they’re experiencing rapid growth. As a result, their value is bound to reach new heights, positioning them as a powerful biological resource at the heart of the global healthcare industry.
+
2021-04-01
Focus on securing greater openness in clinical and commercial approval processes for cell and gene therapies, and explore the establishment of a streamlined "green channel" for the submission and testing of cell- and gene-based therapeutic products. Additionally, support the entry of cutting-edge medical technologies developed overseas into clinical research, and pilot initiatives allowing wholly foreign-owned healthcare providers, health insurance companies, and specialized overseas institutions offering health management services to operate in China.
+
2021-03-19
Stem Cell Therapy: Making 10 Serious Diseases No Longer Scary!
Stem cells are an important biological resource for humans. In recent years, stem cell technology—a rapidly advancing medical innovation—has shown remarkable efficacy in the intervention and treatment of various diseases.
+
2021-03-18
Time flies, yet our original aspirations remain unchanged—our mission still weighs heavily on our shoulders as we forge ahead with determination. In 2021, Jiuzhitang Maker, led by Chairman Zhang Quancheng and General Manager Gao Yansong, will not rest on past achievements. Instead, we’ll stay humble and focused, steadily advancing one step at a time, accelerating as we embark on this new journey!
+
2021-03-08
Li Zhenguo, a deputy to the National People's Congress and Chairman of Jiuzhitang, proposed advancing the high-quality development of traditional Chinese medicine, strengthening the public health security system to safeguard people's health and safety, accelerating the translation of stem-cell technologies into viable pharmaceutical products, fostering rapid, high-quality growth in the industry, and promoting the effective integration of traditional medicine with precision medicine.
+
2021-03-04
With the Two Sessions approaching, several representatives and committee members have offered valuable suggestions for advancing the stem cell industry. This initiative is set to accelerate the development of China's stem cell sector, expedite its clinical translation, and ultimately meet patients' needs while enhancing the health and well-being of people nationwide—providing significant momentum for the field.
+
Here is the title—h1 placeholder text
Copyright © Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd.
Powered by: 300.cn SEO | Privacy Policy